 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This price move could indicate a change in the trend, and may be a sell signal for investors...

Allogene Therapeutics (ALLO, $4.38) price exceeded its 50-day Moving Average on April 01, 2024

Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside...

Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Research analysts at Zacks Research issued their FY2026 earnings per share (EPS) estimates for Allogene Therapeutics in a research report...

Analysts Set Expectations for Allogene Therapeutics, Inc.'s FY2026 Earnings (NASDAQ:ALLO)

This is a signal that ALLO's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

Allogene Therapeutics (ALLO, $4.46) Stochastic Oscillator left the oversold zone on March 28, 2024

Allogene Therapeutics (ALLO, $4.26) price exceeded its 50-day Moving Average on March 22, 2024

HC Wainwright reaffirmed their buy rating on shares of Allogene Therapeutics (NASDAQ:ALLO  Free Report) in a research note released on Tuesday morning, Benzinga reports. HC Wainwright...

Allogene Therapeutics (NASDAQ:ALLO) Receives "Buy" Rating from HC Wainwright

Allogene Therapeutics (NASDAQ:ALLO  Get Free Report)s stock had its buy rating reissued by stock analysts at HC Wainwright in a report issued on Tuesday, Benzinga reports...

Allogene Therapeutics (NASDAQ:ALLO) Stock Rating Reaffirmed by HC Wainwright

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Allogene Therapeutics management to meet with Truist

Allogene Therapeutics, Inc. (NASDAQ:ALLO  Get Free Report)s stock price was down 8.2% during mid-day trading on Thursday . The stock traded as low as $4.48 and last traded at $4.48...

Allogene Therapeutics (NASDAQ:ALLO) Stock Price Down 8.2%

Q4 2023 Allogene Therapeutics Inc Earnings Call Transcript

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Volume (M)	2.01M
52-Wk High	$6.89
52-Wk Low	$2.23

ALLO Allogene Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals